Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
R Kones - Drug design, development and therapy, 2011 - Taylor & Francis
A recent explosion in the amount of cardiovascular risk and incipient, undetected subclinical
cardiovascular pathology has swept across the globe. Nearly 70% of adult Americans are …
cardiovascular pathology has swept across the globe. Nearly 70% of adult Americans are …
Estimating longitudinal risks and benefits from cardiovascular preventive therapies among medicare patients: the million hearts longitudinal ASCVD risk assessment …
DM Lloyd-Jones, MD Huffman, KN Karmali… - Circulation, 2017 - Am Heart Assoc
The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes—the
leading causes of mortality—through several public health and healthcare strategies by …
leading causes of mortality—through several public health and healthcare strategies by …
Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes
NP Johnson, GG Tóth, D Lai, H Zhu, G Açar… - Journal of the American …, 2014 - jacc.org
Background: Fractional flow reserve (FFR) has become an established tool for guiding
treatment, but its graded relationship to clinical outcomes as modulated by medical therapy …
treatment, but its graded relationship to clinical outcomes as modulated by medical therapy …
AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the …
SC Smith Jr, EJ Benjamin, RO Bonow, LT Braun… - Circulation, 2011 - Am Heart Assoc
(ACCF) guidelines on secondary prevention, 1 important evidence from clinical trials has
emerged that further supports and broadens the merits of intensive risk-reduction therapies …
emerged that further supports and broadens the merits of intensive risk-reduction therapies …
Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals
J Yeboah, RL McClelland, TS Polonsky, GL Burke… - Jama, 2012 - jamanetwork.com
Context Risk markers including coronary artery calcium, carotid intima–media thickness,
ankle-brachial index, brachial flow–mediated dilation, high-sensitivity C-reactive protein …
ankle-brachial index, brachial flow–mediated dilation, high-sensitivity C-reactive protein …
Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care
TJ Iwashyna, JF Burke, JB Sussman… - American journal of …, 2015 - atsjournals.org
Randomized clinical trials (RCTs) are conducted to guide clinicians' selection of therapies
for individual patients. Currently, RCTs in critical care often report an overall mean effect and …
for individual patients. Currently, RCTs in critical care often report an overall mean effect and …
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus
S Vijan, JB Sussman, JS Yudkin… - JAMA internal …, 2014 - jamanetwork.com
Importance Type 2 diabetes mellitus is common, and treatment to correct blood glucose
levels is standard. However, treatment burden starts years before treatment benefits accrue …
levels is standard. However, treatment burden starts years before treatment benefits accrue …
Quality of care for patients with multiple chronic conditions: the role of comorbidity interrelatedness
Multimorbidity—the presence of multiple chronic conditions in a patient—has a profound
impact on health, health care utilization, and associated costs. Definitions of multimorbidity …
impact on health, health care utilization, and associated costs. Definitions of multimorbidity …
Estimated benefits of glycemic control in microvascular complications in type 2 diabetes
S Vijan, TP Hofer, RA Hayward - Annals of internal medicine, 1997 - acpjournals.org
Background: The benefits of intensive glycemic control in patients with type 2 diabetes are
not well quantified. It is therefore not clear which patients will benefit most from aggressive …
not well quantified. It is therefore not clear which patients will benefit most from aggressive …
Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health
RA Hayward, HM Krumholz - Circulation: Cardiovascular Quality …, 2012 - Am Heart Assoc
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
are under development and due to be published in 2012. These influential guidelines are …
are under development and due to be published in 2012. These influential guidelines are …